{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-301194","form_type":"8-K","ticker":"ZTS","cik":"0001555280","company_name":"Zoetis Inc.","filed_at":"2021-10-18T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.015935+00:00","generated_at":"2026-06-28T20:17:13.154286+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Zoetis R&D chief Catherine Knupp to retire; Robert Polzer named successor effective Jan 1, 2022","bullets":["Dr. Catherine Knupp will retire as EVP & President of R&D effective Dec 31, 2021.","Robert J. Polzer, current SVP of Global Therapeutics, appointed EVP & President of R&D effective Jan 1, 2022.","Polzer will report to CEO Kristin Peck and join the Zoetis Executive team.","Knupp will remain as advisor through Feb 28, 2022 to assist with transition.","Zoetis highlights over 1,100 new product introductions in the past five years under Knupp's leadership."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-301194","json":"https://secwatch.observer/filing/0001193125-21-301194.json","markdown":"https://secwatch.observer/filing/0001193125-21-301194.md","text":"https://secwatch.observer/filing/0001193125-21-301194.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1555280/000119312521301194/0001193125-21-301194-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1555280/000119312521301194/d467864d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T20:17:13.154286+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4cb229293a","claim":"Robert J. Polzer was appointed as Executive Vice President and President of Research & Development at Zoetis Inc..","evidence_excerpt":"the Company has appointed Robert J. Polzer, PhD, who currently serves as the Company’s Senior Vice President of Global Therapeutics, to succeed Dr. Knupp as the Company’s Executive Vice President and President of Research & Development, effective January 1, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1555280/000119312521301194/0001193125-21-301194-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President and President of Research & Development"}],"fact_type":"executive_change"},{"claim_id":"f41523aa7e","claim":"Catherine Knupp retired as Executive Vice President and President of Research & Development at Zoetis Inc..","evidence_excerpt":"Dr. Catherine Knupp, DVM, MS, the Company’s Executive Vice President and President of Research & Development, has provided notice of her intention to retire from her position, effective December 31, 2021","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1555280/000119312521301194/0001193125-21-301194-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Executive Vice President and President of Research & Development"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}